



Attorney Docket No.: 1506-1032-1

PATENT

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: DIECKMANN et al. Conf. No.: 8230
Appl. No.: 10/619,906 Group: 1614
Filed: July 16, 2003
For: ANTISENSE COMPOUNDS, METHODS AND
COMPOSITIONS FOR TREATING MMP-12
RELATED INFLAMMATORY DISORDERS

L E T T E R

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Date: February 6, 2004

Sir:

Under the provisions of 35 U.S.C. § 119 and 37 C.F.R. § 1.55(a), the applicant(s) hereby claim(s) the right of priority based on the following application(s):

<u>Country</u>	<u>Application No.</u>	<u>Filed</u>
SWEDEN	0202253-1	July 18, 2002

A certified copy of the above-noted application(s) is(are) attached hereto.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

YOUNG & THOMPSON

By Benoît Castel

Benoît Castel, #35,041
745 South 23rd Street, Suite 200
Arlington, Virginia 22202
(703) 521-2297

BC/psf

Attachment

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen



Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

(71) *Sökande* *InDex Pharmaceuticals AB, Stockholm SE*
Applicant (s)

(21) *Patentansökningsnummer* *0202253-1*
Patent application number

(86) *Ingivningsdatum* *2002-07-18*
Date of filing

Stockholm, 2003-07-09

För Patent- och registreringsverket
For the Patent- and Registration Office

Hjördis Segerlund
Hjördis Segerlund

Avgift
Fee *170:-*

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Novel sequence information and methods for its use in diagnosis and therapy XIII**Field of the invention**

The present invention relates to changes in gene expression associated with inflammatory diseases, and in particular inflammatory bowel diseases, gene sequences identified to
5 have such association, and to methods of using such genes or gene products as tools in research, diagnosis or prognosis, or as targets for therapeutic intervention.

Specifically, this invention relates to a novel human gene sequence, which has been identified in colonic mucosa from eight (8) individual patients positively diagnosed with
10 Ulcerative colitis (UC), a subgroup of inflammatory bowel disease. This sequence can *inter alia*: 1) serve as a marker for UC; 2) serve as a marker for inflammatory diseases; and 3) provide means of identifying agents that modulate their expression in colonic mucosa cells and other tissues such that beneficial effects with respect to inflammation can be achieved in a patient.

Background of the invention

15 Inflammatory bowel disease (IBD) comprises several conditions involving chronic inflammation in the gastrointestinal tract. The aetiology of IBD is however poorly understood, and several lines of evidence indicate disordered immune regulation, generation of soluble mediators of inflammation and stimulation by intestinal luminal antigens (e.g., bacteria) as being critical factors. Two of the most debilitating forms of
20 IBD are UC and Crohn's disease (CD). Both UC and CD are recognised as a major health problem of global proportions and there is currently no cure for either condition.

These diseases affect young people, with a typical debut at the age of 20-30 years, and disease management is a long-term commitment for both patient and physician. Whereas the inflammation of UC is restricted to the mucosa and submucosa of colon and rectum,
25 CD shows a wide spread inflammation of the gastro-intestinal tract with granuloma formation.

Current drug treatment regimes focus largely on symptomatic control, but patients often experience periods of relapsed symptoms in the form of nausea, vomiting, bloody diarrhoea, severe abdominal pain and weight loss.

- 5 Patients with long-standing UC are at considerable risk (up to 20 fold over non-UC cases) of developing colorectal cancer and some 50-60 % of IBD patients will require surgical intervention 7-10 years after diagnosis. Resection of the affected area and administration of cytostatic drugs constitute the first line of treatment, however only 30 % of patients respond positively to drug therapy. This equates to a large proportion of patients needing either further surgical treatment or refined medical treatment programs.
- 10 To clinically distinguish UC from colonic CD at an early stage would provide enormous benefits for both the physician and the patient. It would permit the design of accurate treatment regimes, prevent unnecessary medications and reduce treatment costs. Even though the overall clinical picture in IBD patients may show some clinically important differences between the major patient groups of UC and CD, there are substantial
- 15 similarities, thus making it difficult for health care personnel to establish the correct diagnosis. A diagnostic tool that allows discrimination of high cancer risk UC patients from other IBD patients would have significant impacts on the general welfare of the patient, the form of therapeutic regimes administered and if required, the type of surgical intervention deemed most appropriate.
- 20 One way to accurately assess the early manifestation of UC is to identify markers, which are uniquely associated with disease progression. Likewise, the development of therapeutics to prevent or repair colon damage relies on the identification of genes responsible for colon cell growth and function.
- 25 It remains to identify relevant and reliable marker for inflammatory diseases, especially IBDs, and to develop diagnostic, prognostic, and therapeutic tools for such diseases.

Summary of the invention

The present invention is based on the discovery of a novel sequence, differentially expressed in active UC when compared to CD or non-diseased colonic mucosa. The

invention encompasses the isolation of nucleic acid molecules or cDNA molecules as defined in claim 1, and in particular SEQ ID NO. 1, whose expression is altered in humans as a consequence of manifested inflammatory disease, in particular inflammatory bowel diseases.

- 5 The invention further includes the foresaid nucleic acid molecules operably linked to one or more expression control elements. Including but not limited to prokaryotic and eukaryotic vectors harbouring the isolated nucleic acid molecules.

- The invention also includes host cells transformed with these sequences, as well as transgenic animals having these sequences functionally inserted, over-expressed or
10 suppressed, in at least one of their cells. Such animals are useful as research tools for investigations regarding the aetiology of IBDs, the progression, diagnosis and treatment of the same.

The invention in particular provides agents and methods for the modulation, preferably the inhibition, of the expression of the genes identified by the sequence SEQ. ID. NO. 1.

- 15 The invention is further defined in the attached claims, incorporated herein by reference.

Brief Description of the Drawings

The invention will be described in closer detail in the following description, examples and figures, in which

Fig. 1 (drawings not submitted at date of priority)

20

Description of the invention

- Before the present method is disclosed and described, it is to be understood that this invention is not limited to the particular configurations, process steps, and materials disclosed herein as such configurations, process steps, and materials may vary somewhat. It is also to be understood that the terminology employed herein is used for the purpose of
25 describing particular embodiments only and is not intended to be limiting since the scope

MH 47381

- 4 -

of the present invention will be limited only by the appended claims and equivalents thereof.

In the description, examples and claims, the following terms will be used (defined in alphabetical order):

- 5 "Antisense" as in "antisense molecules" and "antisense sequences" refers to single stranded RNA or DNA molecules complementary to a portion of the mRNA of a target gene. The antisense molecule will base-pair with the mRNA, thus preventing translation of the mRNA into protein. Consequently, the term "antisense therapy" refers to methods using such antisense compounds which specifically hybridise to a target nucleic acid and
10 modulate its function or translation, for example by suppressing or reducing the expression of gene products coded by said sequence.

"Complementary" in the context of this description refers to the capacity for precise pairing between two nucleotides.

"Hybridisation" means bonding between complementary nucleoside or nucleotide bases.

- 15 "Hybridisation under stringent conditions" refers to the criteria regarding temperature and buffers well known in the field.

- "Functionally homologous" means sequences sharing perhaps a lower structural homology with the disclosed sequences, but exhibiting homologous function in vivo, in either the healthy or the diseased organism, e.g. coding the same or highly similar
20 proteins.

- "Functionally inserted" or "operationally inserted" denotes that a sequence has been inserted in a host genome in such orientation, location and with such promoters, where applicable, that the correct expression of said sequence occurs. "Modulation" as used in this context means either an increase (stimulation) or a decrease (inhibition) in the
25 expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

"PNA" or peptide nucleic acids are synthetic chimeras of nucleobases linked to a peptide backbone.

SEQ. ID. NO. 1: This patent refers to a gene called metalloproteinase 12 (MMP12).

Matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases collectively capable of degrading essentially all matrix components. They seem to play an essential role in cancer progression and inflammation. MMP-12 is also called macrophage metalloelastase and it has now surprisingly been shown that this enzyme is upregulated in IBD.

The identified sequence (SEQ. ID. NO. 1) seems to match Acc# XM_058069.

10

Specific Embodiments

Diagnostic applications

The sequences disclosed herein, and information derivable thereof, such as gene fragments and full length sequences identifiable using the described sequence (SEQ. ID. NO. 1), enables new diagnostic approaches. By determining the presence or absence of such sequence, or the expression or translation of the same, indications to the presence or absence of inflammatory states can be obtained. The nucleic acid molecules, or proteins or antibodies derived thereof, according to the present invention may be labelled or conjugated to a variety of labels or other molecules, normally employed in diagnostic applications, such as fluorescent markers, enzymatic markers, toxic molecules, molecules which are non-toxic but become toxic upon exposure to a second compound, and radionuclides.

Diagnostic methods according to the invention also involve the detection of low level expression of said sequence (SEQ. ID. NO. 1) or gene fragments or full length sequences identifiable through the sequence disclosed herein. Patient samples, such as biopsy samples, samples of body fluids such as blood, serum, lymphatic fluid, urine or faeces may be utilized, and the presence or absence of gene expression determined according to methods well known in the art. In many cases, the availability of sample may be limited,

and methods of *in vitro* amplification of the cDNA may have to be resorted to. An example of such methods is given in the Examples section of the present description.

Prognostic applications

Prognostic applications of the inventive sequences involves the detection of low level
 5 expression of said sequence (SEQ. ID. NO. 1) or gene fragments or full length sequences
 identifiable through the sequences disclosed herein. Patient samples, such as biopsy
 samples, samples of body fluids such as blood, serum, lymphatic fluid, urine or faeces
 may be utilized, and the presence or absence of gene expression determined according to
 methods well known in the art. In many cases, the availability of sample may be limited,
 10 and methods of *in vitro* amplification of the cDNA may have to be resorted to. An
 example of such methods is given in the Examples section of the present description.

Therapeutic applications

The present invention provides different therapeutic methods, based on the regulation of
 the genes, identified by the sequence of the present invention (SEQ. ID. NO. 1), including
 15 methods for the down-regulation or suppression of the expression of said genes.

Antisense technology is emerging as an effective means for reducing or suppressing the
 translation of specific genes and the expression of specific gene products, and may
 therefore be useful for the treatment of inflammatory diseases, based on the specific
 sequences disclosed in the present description. The present invention thus provides
 20 methods and compositions for use in antisense therapy.

In particular, the present invention provides a compound 8 to 50 nucleobases in length
 targeted to a nucleic acid molecule identified by comprising a sequence according to
 SEQ. ID. NO. 1, or parts thereof, wherein said compound hybridises with and modulates,
 preferably inhibits, the expression of said nucleic acid molecule.
 25 Said compound should be able to exhibit specific and stable hybridisation, and preferably
 said compound comprises 8 to 24 nucleobases in length. Most preferably, said compound
 has a sequence comprising at least an 8-nucleobase portion of SEQ. ID. NO. 1.

MH 47381

- 7 -

According to a preferred embodiment, said compound is an antisense oligonucleotide. According to a further embodiment, said antisense oligonucleotide comprises at least one modified nucleobase, which may be chemically modified by substitution in a non-bridging oxygen atom of the antisense nucleic acid backbone with a moiety selected from the group consisting of methane phosphate, methyl phosphate and phosphorothioate. According to one embodiment, said substitution is at one or more nucleotides independently selected from the final three nucleotides at the 3' terminus and 5' terminus of said oligonucleotide. It is also conceived, that the substitution occurs at any position along the entire length of said oligonucleotide. Preferably, said oligonucleotide comprises at least one modified sugar moiety nucleobase, and the modified sugar moiety may be a 2'-O-methoxyethyl sugar moiety.

Said antisense agent may also be an antisense agent composed of DNA or RNA or an analogue or mimic of DNA or RNA including but not restricted to the following: methylphosphonate, N3'->P5'-phosphoramidate, morpholino, peptide nucleic acid (PNA), locked nucleic acid (LNA), arabinosyl nucleic acid (ANA), fluoro-arabinosyl nucleic acid (FANA) methoxy-ethyl nucleic acid (MOE). Preferably said antisense agent is a homo or heteropolymer containing combinations of the above DNA or RNA or analogues or mimics of DNA or RNA.

The present invention also makes available a pharmaceutical composition, wherein said composition comprises a compound or antisense agent as describe above, and a pharmaceutically acceptable carrier or diluent. Said pharmaceutical composition preferably further comprises a colloidal dispersion system.

The present invention also makes available a method of inhibiting the expression of a gene identified by comprising a sequence according to SEQ. ID. NO. 1 in human cells and tissues, comprising said human cells and tissues *in vivo* or *in vitro*, wherein that a compound or antisense agent as described above is used.

The present invention also provides a variety of pharmaceutical compositions, comprising eukaryotic cells transformed with any of the disclosed sequences, SEQ. ID. NO. 1, along with a pharmaceutically or physiologically acceptable carrier, excipients or diluents.

Generally, such carriers should be non-toxic to the recipient at the dosages and concentrations used. Ordinarily, the preparation of such compositions involves combining the therapeutic agent with one or more of the following: buffers, antioxidants, low molecular weight polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrans, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with non-specific serum albumin are examples of suitable diluents. Such compositions may find use in gene therapy applications. Such compositions according to the present invention may be administered in a number of ways depending on whether local or systemic treatment is desired.

Administration according to the present invention is preferably topical, and local, as in rectal or oral delivery to the mucous membranes of the gastrointestinal tract. Formulations for gastrointestinal administration include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners etc may be used as desired. Solutions, emulsions and liposome-containing formulations are included. A preferred form of administration is a liquid, preferably water based formulation, administered rectally in the form of an enema.

Gene therapy according to the present invention is not limited to the treatment of a manifest disease, in particular an inflammatory bowel disease, but also encompasses the prevention of the onset or recurrence of such diseases.

Further, antisense compounds are commonly used in research and diagnostics. Antisense oligonucleotides, which are able to inhibit gene expression with great accuracy, may be used to elucidate the function of particular genes and thereby offer novel therapeutic strategies for the treatment of inflammatory disorders. The present invention encompasses such applications of antisense compounds, based on the information contained in the sequences disclosed herein, or directed to genes identifiable therewith.

Transgenic cells and animals

The present invention also provides transgenic cells as such, as well as transgenic animals. Transgenic animals include animals comprising viable transgenic cells, or

transgenic organs, as well as entire animals incorporating any one of the inventive sequences (SEQ. ID. NO. 1) or functional parts thereof, in their genome. The inventive sequences may be over-expressed, suppressed or unregulated in said transgenic cells, organs or animals.

- 5 One embodiment of the present invention is thus such transgenic cells, organs or animals, and their use as models for investigating the nature and/or aetiology of inflammatory diseases, in particular IBDs, as models for evaluating the efficacy of pharmaceuticals against such diseases, as well as investigating the effect of known and suspected causative agents behind such diseases.

10 **Examples**

Identification of the appropriate biopsy material

- The biopsies were taken from patients who were selected on the basis of clinical and pathological anatomical evidence of having UC, with or without the complication of colorectal dysplasia or cancer. A total of three (3) biopsies per anatomical site are
15 collected from the colon of a single individual patient. That is 3 biopsies from the active inflamed site (active target tissue) and 3 biopsies from non-inflamed area (normal control tissue). This was done for eight (8) different patients.

Isolation of differentially expressed total RNA

- The biopsies of each anatomical site of one patient was pooled and total RNA was
20 isolated using Quiagen Rneasy Kit and a Pellet Pestel Motor Homogenizer according to the manufacturers protocol. In this way 16 samples of total RNA were isolated, two samples per patient: inflamed (target) and non-inflamed (control).

Performing cDNA synthesis of the RNA

- Two microgram of each RNA sample (16) was used for a first strand cDNA synthesis
25 using 10pM of the Oligo-dT-primer dT-joint (5'-TAG TCT ATG ATC GTC GAC GGC TGA TGA AGC GGC CGC TGG AGT TTT TTT TTT TTT TTT TTV-3' (SEQ. ID. NO. 101)) introducing to every synthesised cDNA molecule three restriction enzyme cutting

sites: SalI, NotI and BpmI. The buffer, the desoxynucleotide triphosphates (dATP, dCTP, dGTP and dTTP) and the enzyme reverse transcriptase (Superscript II) were taken from Gibco BRL and the reactions were done as described in the protocol supplied with the material. The reaction mixture for first strand synthesis excluding the enzyme was
5 preincubated for 5 min at 65°C in a PCR machine (PCR sprint from Hybaid), chilled on ice, preheated to 42°C, the enzyme Superscript II was added and incubated for 1h at 42°C in a PCR machine (PCR sprint from Hybaid).

For the second strand synthesis 41 µl second strand buffer mix were added to the reactions according to the provided protocol (Gibco BRL) and 4µl *E.coli* Polymerase I
10 (New England Biolabs), 1.5 µl *E.coli* DNA ligase (New England Biolabs) and 0.7 µl Rnase H (Gibco BRL) in a total volume of 160 µl. These reactions were incubated for 2.5h at 16°C in the PCR machine PCR sprint and then purified using the Quiagen PCR Purification Kit according to the protocol provided. Every sample (16 in total) was eluted with 32 µl of elution buffer and 26 µl of each sample was used for the following steps.

15 Amplification of the 3'-termini of the cDNAs

The amount of material isolated and processed out of biopsies is very restricted. Consequently, the present inventors used the new method described in co-pending application SE 0200035-4, incorporated herein by reference, for *in vitro* amplification of the 3'-end of cDNA.

20 For *in vitro* amplification of the 3'-end of cDNA 26 µl cDNA of every sample (16 in total) was digested with 10U of the restriction enzyme DpnII in a volume of 30 µl for 3h at 37°C. Then the cut cDNAs were purified once more using Quiagen PCR purification Kit and the cDNAs were eluted in 47 µl elution buffer. The following circular ligation
25 step was performed in a volume of 50 µl including 44 µl of the DpnII cut cDNA and 2000U T4 DNA ligase (New England Biolabs). These reaction mixtures were incubated at 22°C for 1h, heat inactivated by 65°C for 10 min and 25 µl of each reaction mixture was used for the amplification step. A mixture for 5 reactions per sample was put together (5x 50 µl= 250 µl in total) containing 25 µl cDNA (DpnII cut and circular

ligated), 25 µl 10x Advantage 2 PCR buffer (Clontech), 5 µl joint-Not primer (10 pmol/µl; 5'-TGA TGA AGC GGC CGC TGG-3' (SEQ. ID. NO. 102)), 5 µl joint-Sal primer (10pmol/µl; 5'- TTC ATC AGC CGT CGA CGA TC -3' (SEQ. ID. NO. 103), 5 µl 10mM dNTP mix and 5 µl 50x Advantage 2 Taq-Polymerase (Clontech). For each
5 sample (16 in total) the mix was distributed into 5 PCR reaction tubes and PCR performed under the following conditions: 1 min 94°C then 16x (20 sec 94°C, 20 sec 55°C, 1 min 72°C).

Four of the reactions per sample were removed and placed on ice and the optimal cycle number was determined with one of the reactions per sample. The optimal cycle number
10 was determined to 18 cycles for all 16 samples, thus for the remaining four reactions per sample two additional cycles [2x (20 sec 94°C, 20 sec 55°C, 1 min 72°C)] were performed. The 4 PCR reactions per sample were subsequently purified using the Quiagen PCR purification Kit. For the purification, the four reactions per sample were pooled (total of 200 µl) and then eluted with 34 µl elution buffer. The purified reactions
15 were the working material for the identification of the differentially expressed genes.

Isolation of the differentially expressed cDNA (subtraction protocol)

To isolate differentially expressed genes via a PCR based subtraction method different primer adaptors have to be ligated to a part of the cDNA. Thus, cDNA has to be prepared. A second goal for the following processing of the cDNA is to remove the Oligo-dT tail
20 for a more specific subtraction.

For the preparation of the adaptor ligation 26 µl of the cDNAs was Sal I digested in a volume of 30 µl with 10U Sall for 2h at 37°C. The cDNAs were then purified using the Quiagen PCR purification Kit and eluted with 35 µl elution buffer. Then a partial fill in reaction was performed for the ligation of the 5' adaptors by taking 33 µl of each cDNA
25 sample (Sall cut) and incubating it for 1h at room temperature with 20U of the Klenow fragment of DNA polymerase in the presence of dTTP (1µl of 10 mM in 40 µl volume) to destroy the SalI ends, which will be restored in the part of the cDNA which the 5' adaptors will be ligated to. The samples were then purified again using the Quiagen PCR

purification kit, eluted with 36 µl of elution buffer and 33 µl was used for a BpmI digest to remove the Oligo-dT tail and to prepare the 3' ends for the ligation of the 3' adaptors. The cDNAs were incubated with 6U BpmI for 2h at 37°C. After the next purification step with Quiagen PCR purification kit, the concentration of the cDNAs were estimated on a 1% agarose gel so that the concentration of the cDNAs of one patient, i.e. both target and control, are approximately the same.

Adaptor ligation to a part of the cDNA samples ("tester" cDNA generation)

To have the possibility to enrich the genes that are differentially expressed in all eight patients, the present inventors developed a PCR amplification system ("pyramide; described below). To perform this part, two different 5' and 3' adaptors (instead of one each) were ligated to the ends, which differ from usual PCR based subtraction protocols.

Table 1 shows the volume in µl of each cDNA sample used for the adaptor ligation and with which adaptors each patient cDNA was ligated. One ligation reaction contained the cDNA of one sample (16 in total) and from each sample two reactions were performed (with two different adaptors), making it a total of 32 reactions. In one reaction 40 pM adaptor and 2000U of T4 Ligase (New England Biolabs) was used and the reactions were incubated for 4h at 22°C.

Table 1.

Patient	Sample type	Applied cDNA	Adaptor
Patient A	c	4	1+2
	t	2	1+2
Patient B	c	2	1+2
	t	2	1+2
Patient C	c	2	1+2
	t	2	1+2
Patient D	c	2	1+2
	t	4	1+2
Patient E	c	2	3+4
	t	2	3+4
Patient F	c	2	3+4
	t	2	3+4
Patient G	c	2	3+4
	t	2	3+4

MH 47381

- 13 -

Patient H	c	2	3+4
	t	2	3+4

For the adaptor ligation the adaptors had to be made out of two oligonucleotides, which were annealed to form double strand molecules. The oligonucleotide sequences were:

- 5 Ada-1L: 5'- AAC CAC CTG CGA GTA CAA TCT GGG CGG CCG CAG TCT T-3'
(SEQ. ID. NO. 103)

Ada-2L: 5'- GCA CTC GTA TGG TTG TAG TTG CGG CGG CCG CAG TCT T-3'
(SEQ. ID. NO. 104)

- 10 Ada-3L: 5'- TCG TTA GCG TGC TGT CAT TCC TGG GGG CCG CAC AG-3'
(SEQ. ID. NO. 105)

Ada-4L: 5'- GGA ACA GTA GCA GGG TTT GTC TCG GGG CCG CAC AG-3'
(SEQ. ID. NO. 106)

Ada-1/2S: 5'- GAC TGC GGC CG-3' (SEQ. ID. NO. 107)

Ada-3/4S: 5'- CGA CTG TGC GGC CC-3' (SEQ. ID. NO. 108)

- 15 The oligonucleotides Ada-1L and Ada-2L were annealed to the oligonucleotide Ada-1/2S to get adaptors Ada1 and Ada2. To form adaptors Ada3 and Ada4 the oligonucleotides Ada-3L and Ada-4L were annealed to the oligonucleotide Ada-3/4S. This was done in 40 ml reactions where 18 ml of 200 pmol/ml stock solution of both oligonucleotides in 1x SalI buffer were placed into a sealed tube and then submerged in 1 ltr of boiling water and subsequently put in room temperature for 5-6h for cooling down. After this procedure, 5 ml of each annealed adaptor was sampled, and 45 ml water added to provide a stock solution of 20 pmol/μl, which was then used in the adaptor ligation reaction.
- 20

After the ligation reaction 16 μl 10 mM Tris pH 8.0 was added to the cDNA samples ("tester cDNA", 32 in total).

Driver cDNA generation

The rest of the purified BpmI digested cDNA samples was lyophilized by incubation with an open lid in a heating oven at 50°C. The pellets were then dissolved in water in order to become 2x concentrated with respect to the tester cDNA (see table 2).

5 Table 2: Amount of applied water (µl)

Patient	Sample type	Applied water (µl)
Patient A	c	7.5
	t	13
Patient B	c	13
	t	7.5
Patient C	c	13
	t	13
Patient D	c	13
	t	13
Patient E	c	13
	t	13
Patient F	c	13
	t	13
Patient G	c	7.5
	t	13
Patient H	c	13
	t	13

Subtractive Hybridisation

10 In order to subtract the non-differentially expressed genes from the differentially expressed genes, the target cDNA (tester) was subtracted against an excess of control cDNA (driver). The subtraction reaction is a normal hybridisation step of two denatured cDNAs, which can only anneal at high temperature because they share at least 70% identity. The present inventors performed two subtractions per patient, in total 16 subtractions. For each subtraction two hybridisation steps were performed. In the first hybridisation the driver cDNA is incubated with only one type of tester cDNA, which

15 means two reactions, A and B, per sample and subtraction (see tab 3). In table 3 the composition of the reactions for the first hybridisation step is shown. Altogether this were

32 reactions; Ada A stands for Ada 1 or 3 and Ada B stands for Ada 2 or 4 (see also tab 2). The reactions were incubated at 98°C for 1.5 min in PCR tubes and then at 68°C for 8-9h.

Table 3. Composition of the reactions in the first hybridisation step

	Reaction A	Reaction B
Driver	1.5 µl	1.5 µl
Tester (+ Ada A)	1.5 µl	/
Tester (+ Ada B)	/	1.5 µl
4 x Hyb buffer	1 µl	1 µl
Mineral oil	10 µl	10 µl

5

In the second hybridisation step the two reactions, A+B, were combined and additional driver cDNA was added. To perform this step, fresh PCR tubes were used and 0,5 µl driver (target or control as before depending on the subtraction), 0,5 µl 4xHyb buffer, 1 µl H₂O and 6 µl mineral oil was added to the tubes and subsequently incubated at 98°C for 1,5 min. The reactions from the first hybridisation were then added to the new PCR tubes, so that reactions A+B were combined with new excess of driver (16 reactions in total), and the combined samples incubated over night at 68°C.

10

In order to remove the annealed fragments with lower identity, 200 µl of dilution buffer (20 mM Hepes pH 8.0, 50 mM NaCl, 0.2 mM EDTA) was added and incubated for an additional 10 min at 68°C.

15

PCR amplification of enriched genes

After this subtraction procedure the non-subtracted specific gene fragments were amplified using the ligated adaptors (see tab.1) to prime the oligonucleotides. The

subtracted cDNA of patients A to D was amplified with the oligo primers ad1 and ad2 and the cDNA of patients E-H with the primers ad3 and ad4 (Note: for each patient two reactions were done for up and down regulation giving a total of 32 reactions).

The sequences of the used oligonucleotide primers are:

5 Ad1: 5'-AAC CAC CTG CGA GTA CAA TCT GG-3' (SEQ. ID. NO. 109)

Ad2: 5'-TCG TTA GCG TGC TGT CAT TCC TG-3' (SEQ. ID. NO. 110)

Ad3: 5'-GCA CTC GTA TGG TTG TAG TTG CG-3' (SEQ. ID. NO. 111)

Ad4: 5'-GGA ACA GTA GCA GGG TTT GTC TC-3' (SEQ. ID. NO. 112)

For the PCR reaction 5 ml of the hybridisation sample was used, 5 µl of the 10x
10 Advantage 2 PCR buffer of Clontech, 1 µl of primer ada 2 or 4, 1 µl of primer ada 1 or 3,
1 µl of 1 mM dNTP mix and 1 µl 50xAdvantage 2 Taq polymerase of Clontech in a total
volume of 50 µl. The cycling parameters were 75°C for 3 min, 94°C for 1 min and then
28 times 94°C for 20 sec, 68°C for 20 sec and 72°C for 1 min.

Two reactions per sample were combined and 5 µl run on an agarose gel, the remaining
15 95 µl was purified using Quiagen PCR purification kit and eluted with 30µl elution
buffer. Of the amplified and purified cDNAs were 20 µl used as the material for the
pyramid enrichment.

Further enrichment of the differentially expressed genes (pyramid protocol)

After the first amplification step (described in "PCR amplification of enriched genes")
20 one adaptor was cut off from one end of the cDNA fragments of each patient and then
cDNA from two patient were combined in a way that after the hybridisation step and
refill step only the these cDNAs that were enriched in both patients could be amplified.
For example, patient A has ada2 as 5'-adaptor and ada1 as 3'-adaptor, patient B has ada4
as 5'-adaptor and ada3 as 3'-adaptor. The cDNA of patient A was cut with SalI which
25 will only cut the 5'-adaptor, and the cDNA of patient B was cut with NotI, which

- likewise, will only cut the 3'-adaptor. When they are mixed and hybridised, only the cDNAs that are enriched in both patients could find each other and be amplified after a fill-in reaction. The cDNAs that are only enriched in one patient find their complementary strand, but they are missing the second adaptor for amplification. The new "hybrids" can then be amplified with the oligo primers ad4 (5'-end primer) and ad1 (3'-primer). The individual steps of the pyramid are shown in tab.4. The pyramid was performed twice for up- and down subtraction.

Table 4. Scheme of the pyramid protocol

Reaction	Patient A	Patient B	Patient C	Patient D	Patient E	Patient F	Patient G	Patient H
Amplification 1	2 + 1	4 + 3	1 + 2	4 + 3	2 + 1	4 + 3	2 + 1	4 + 3
Digest 1	Sall	NotI	NotI	Sall	NotI	Sall	Sall	NotI
Hybridisation 1	Patient samples A + B		Patient samples C + D		Patient samples E + F		Patient samples G + H	
Amplification 2	4 + 1		2 + 3		2 + 3		4 + 1	
Digest 2	Sall		NotI		Sall		NotI	
Hybridisation 2	Patient samples A + B + C + D				Patient samples E + F + G + H			
Amplification 3	2 + 1				4 + 3			
Digest 3	Sall				NotI			
Hybridisation 3	Patient samples A + B + C + D + E + F + G + H							
Amplification 4	4 + 1							
Digest 4	Sall + NotI							

MH 47381

- 18 -

Digest protocol:

For each digest 20 µl of 30 µl purified cDNA was used in a volume of 30 µl. The cDNA was digested with 10U of SalI or NotI for 3h at 37°C and subsequently heat inactivated for 20 min at 65°C.

5 **Hybridisation protocol:**

Three µl of sample A was combined with 3 µl of sample B in 1x hybridisation buffer in a volume of 8 µl, covered with 15 µl mineral oil. The reaction was performed in a PCR machine for 13h at 68°C. The reaction was then diluted with 500 µl dilution buffer and 5 µl was used for the next PCR amplification step.

10 **Amplification protocol:**

For the PCR reaction 5 µl of the hybridisation sample was used, 5 µl of the 10x Advantage 2 PCR buffer of Clontech, 1 µl of primer ada 2 or 4, 1 µl of primer ada 1 or 3, 1 µl of 1 mM dNTP mix and 1 µl 50x Advantage 2 Taq polymerase of Clontech in a total volume of 50 µl. The cycling parameters were 75°C for 3 min, 94°C for 1 min and then 15 13 times 94°C for 20 sec, 68°C for 20 sec and 72°C for 1 min. The PCR reactions were then purified using Quiagen PCR purification kit and eluted with 30 µl elution buffer.

Cloning the enriched differentially expressed genes into a vector

After the last amplification step of the protocol (amplification 4 see tab.4) the remaining enriched cDNA was digested with SalI and NotI as previously described and purified 20 using Quiagen PCR amplification kit. The cDNAs were eluted with 30 µl elution buffer and 6 µl of each cDNA (up and down) was used for ligation into pSPORT 1 vector (GIBCO Brl, pre-cut with SalI and NotI). Two µl of the vector and 10U of T4 ligase (New England Biolabs) was added and incubated for 5h at room temperature.

One µl of each ligated sample (up and down) was transformed into 50 µl Chemomax efficiency DH5a competent cells (Gibco BRL) according to the manufacturers 25 instructions.

Screening for the differentially expressed genes

After estimating the colony number per μl transformation sample, approximately 8.000 clones were plated out from each subtraction, distributed on two 22 cm^2 agar plates (4.000 colonies/plate). From these plates 6x 384 colonies were picked and placed in 384 well plates with 70 μl LB medium/well (see Maniatis *et al.*, Molecular cloning laboratory book, Appendix A.1) (+ ampicillin 100 mg/ml) using *BioPick* machine of *BioRobotics* (Cambridge, UK). The bacterial clones were incubated over night at 37°C and then used for colony PCR. This PCR was performed in 384 PCR well plates in a volume of 20 μl per sample. One PCR reaction included: 2 μl 10x PCR buffer, 0,4 μl Sport-Not primer (10 pmol/ μl ; 5'-CGT AAG CTT GGA TCC TCT AGA GC-3' (SEQ. ID. NO. 113), 0,4 μl of Sport-Sal primer (10 pmol/ μl ; 5'-TGC AGG TAC CGG TCC GGA ATT CC-3' (SEQ. ID. NO. 114)), 1,6 μl dNTP mix (25 mM each), 0,4 μl 0,1% Bromphenol blue and 0,5 μl DynAzyme Taq-polymerase (2 U/ μl ; FynZyme). A master mix for all reactions was prepared, distributed and then inoculated with a 384 plastic replica. The PCR cycling parameters were: 2 min 94°C, 37 times (30 sec 94°C; 30 sec 50°C, 1 min 72°C) and 5 min 72°C.

Following the amplification, the PCR reactions were spotted on Hybond N+ membrane (Amersham) using Microgrid TAS of *BioRobotics*. All clones were spotted in duplicates and genomic DNA was used as guide dots. On one filter all 6x384 up-regulated genes and all 6x384 down-regulated genes were positioned. 24 duplicates were made for analyses by hybridisation with different radioactive cDNA probes.

Hybridisation conditions: ...

Identification of the differentially expressed genes

Phospho-imager Fujifilm BAS 1800II with BAS 1800 III R program, Arrayvision version 6.0 (Imaging Research Inc), sequencing, BLAST analysis

Confirmation of the differential expression

RT-PCR...

MH 47381

- 20 -

Although the invention has been described with regard to its preferred embodiments, which constitute the best mode presently known to the inventors, it should be understood that various changes and modifications as would be obvious to one having the ordinary skill in this art may be made without departing from the scope of the invention as set
5 forth in the claims appended hereto.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2

SEQUENCE LISTING

<110> INDEX PHARMACEUTICALS AB

DIECKMANN, Andreas

LÖFBERG, Robert

VON STEIN, Oliver

VON STEIN, Petra

<120> Novel sequence information and methods for its use in diagnosis and therapy XIII

<130> MH 47381

<160> 1

<170> PatentIn version 3.1

<210> 1

<211> 426

<212> DNA

<213> Homo sapiens

<400> 1

tttggatatg acttctact ccaacgtatc accaaaacac tgaaaagcaa tagctggt
tt 60

ggttgtaga aatgggtgtaa ttaatgggtt ttgtagttc acttcagctt aataagta
tt 120

tattgcatat ttgctatgtc ctcagtgtac cactacttag agatatgtat cataaaaa
ta 180

aaatctgtaa accataggta atgattatat aaaatacatg atatTTTTca attttgaa
aa 240

ctctaattgt ccattcttgc ttgactctac tattaagttt gaaaatagtt accttcaa
ag 300

gccaaagagaa ttttatttga agcatgctct gtaagttgct tctaacatc cttggact
ga 360

gaaattatac ttacttctgg cataactaaa attaagtata tatattttgg ctcaaata
aa 420

attgaa
426

Claims

1. An isolated and purified nucleic acid molecule comprising a polynucleotide selected from
 - (a) a nucleotide sequence at least 70 % identical to the sequence of SEQ. ID. NO. 1,
 - 5 (b) a nucleotide sequence complementary to the sequence of (a),
 - (c) a nucleotide sequence which hybridises under stringent conditions to the sequence of (a),
 - (d) a nucleotide sequence functionally homologous to the sequence of SEQ. ID. NO. 1.
- 10 2. An isolated and purified nucleic acid molecule according to claim 1(a), **characterized** in that the sequence exhibits at least 80 % homology to the sequence of SEQ. ID. NO. 1.
3. An isolated and purified nucleic acid molecule according to claim 1(a), **characterized** in that the sequence exhibits at least 90 % homology to the
15 sequences of SEQ. ID. NO. 1.
4. An isolated and purified nucleic acid molecule according to claim 1, **characterized** in that the polynucleotide is a DNA molecule.
5. An isolated and purified nucleic acid molecule according to claim 1, **characterized** in that the polynucleotide is a cDNA molecule.
- 20 6. An isolated and purified nucleic acid molecule according to claim 1, **characterized** in that the polynucleotide is a RNA molecule.
7. A PNA molecule capable of hybridising to a nucleic acid molecule according to claim 1.
8. A method of producing a recombinant vector, **characterized** in that the isolated
25 nucleic acid of claim 1 is functionally inserted into a vector.

9. A recombinant vector produced by the method of claim 8.
10. A recombinant vector, **characterized** in that the isolated nucleic acid of claim 1 is operatively linked to regulatory sequences which control the expression of said nucleic acid sequence.
- 5 11. A recombinant vector, **characterized** in that the isolated nucleic acid of claim 1 is operatively linked to regulatory sequences which, due to the intrinsic orientation of the said nucleic acid, produces an antisense nucleic acid that's is complementary to the target sequences and hybridizes to the target sequence.
- 10 12. A method of producing a recombinant host cell, **characterized** in that the recombinant vector of claim 9 or 10 is introduced into a host cell.
13. A recombinant host cell produced by the method of claim 12.
14. A transgenic non-human animal, **characterized** in that said animal carries at least one sequence according to claim 1 operationally inserted in at lease one cell.
- 15 15. A method of screening a human subject for susceptibility to inflammatory diseases, in particular but not limited to an inflammatory bowel disease, **characterized** in said method comprising a step of screening for the presence or absence of the expression of, or the degree of expression of a sequence according to claim 1.
- 20 16. A method of diagnosing an inflammatory disease in a human subject, in particular but not limited to an inflammatory bowel disease, **characterized** in that the degree of expression of a sequence according to claim 1 is determined.
- 25 17. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule identified by comprising the sequence of claim 1, **characterized** in that said compound hybridises with and inhibits the expression of said nucleic acid molecule.

MH 47381

- 24 -

18. The compound according to claim 17, **characterized** in that the compound comprises 8 to 24 nucleobases in length.
19. The compound of claim 17, **characterized** in that said compound is an antisense oligonucleotide.
- 5 20. The compound of claim 17, **characterized** in that said compound has a sequence comprising at least an 8-nucleobase portion of SEQ. ID. NO. 1.
21. The compound of claim 19, **characterized** in that said antisense oligonucleotide comprises at least one modified nucleobase.
- 10 22. The compound of claim 17, **characterized** in that said antisense oligonucleotide is chemically modified by substitution in a non-bridging oxygen atom of the antisense nucleic acid backbone with a moiety selected from the group consisting of methane phosphate, methyl phosphate and phosphorothioate.
- 15 23. The compound of claim 17, **characterized** in that it is an antisense agent composed of DNA or RNA or an analogue or mimic of DNA or RNA including but not restricted to the following: methylphosphonate, N3'->P5'-phosphoramidate, morpholino, peptide nucleic acid (PNA), locked nucleic acid (LNA), arabinosyl nucleic acid (ANA), fluoro-arabinosyl nucleic acid (FANA) methoxy-ethyl nucleic acid (MOE).
- 20 24. The antisense agent of claim 23, **characterized** in that said agent is a homo or heteropolymer containing combinations of the above DNA or RNA or analogues or mimics of DNA or RNA.
- 25 25. The compound of claim 22, **characterized** in that the substitution is at one or more nucleotides independently selected from the final three nucleotides at the 3' terminus and 5' terminus of said oligonucleotide.
26. The compound of claim 22, **characterized** in that the substitution occurs at any position along the entire length of said oligonucleotide.

MH 47381

- 25 -

27. The compound of claim 22, **characterized** in that said oligonucleotide comprises at least one modified sugar moiety nucleobase.
28. The compound of claim 27, **characterized** in that the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 5 29. A pharmaceutical composition, **characterized** in that said composition comprises a compound according to any one of claims 16 - 28 and a pharmaceutically acceptable carrier or diluent.
30. The composition of claim 29, **characterized** in that said composition further comprises a colloidal dispersion system.
- 10 31. A method of inhibiting the expression of a sequence according to claim 1 in human cells and tissues, comprising said human cells and tissues *in vivo* or *in vitro*, **characterized** in that a compound according to any one of claims 16 - 28 is used.

MH 47381

- 26 -

Abstract

Variations in the expression of SEQ. ID. NO. 1 is shown to be associated with inflammatory diseases, and in particular inflammatory bowel disease. The invention provides oligonucleotide sequences identified to have such association, and methods of
5 using such genes or gene products as tools in research, diagnosis or prognosis, or as targets for therapeutic intervention.
